Farxiga

Farxiga (generic name: dapagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Farxiga acts as a blocker for the SGLT2 protein, which is situated in the early parts of the kidney tubules. Its primary function is to reabsorb the glucose from the filtered liquid back into the body. By doing this, the drug ensures that more glucose is expelled through urine rather than being taken back into the blood. Beyond its effect on glucose, Farxiga also impacts how the kidneys handle salt. This can lead to several physiological effects, including reducing the workload on the heart, moderating specific body signals, and potentially decreasing the internal pressure within the kidney’s filtering units. Outcomes include: An improvement in glycemic control in adults with type 2 Diabetes A reduction in the risk of sustained kidney decline A reduction in the risk of hospitalization for heart failure in adults with diabetes or kidney decline Dosage Dosage is dependent on the underlying condition. It is essential to follow the prescribing healthcare professional’s instructions and read the Patient Information leaflet that comes with the package.